Celine Halioua — Podcast Appearances & Summaries

Featured On 1 Podcast

Venture Stories

3 episodes

All Appearances

3 episodes

[Highlight] What Happens to Society When We Live to 100? with Celine Halioua

Venture Stories

Feb 24, 202611 min

AI Summary

→ WHAT IT COVERS Celine Halioua, CEO of Loyal, discusses longevity's shift from supplements to FDA-approved drugs, the societal restructuring required when humans routinely live past 100, and how cognitive aging drugs could reshape cultural flexibility. → KEY INSIGHTS - **FDA Drug Approval as Inflection Point:** Longevity remains associated with supplements and biometric optimization rather than medicine. The first FDA-approved lifespan-extension drug will reframe aging as a treatable pathological process, separating physiological decline from chronological age as a measurable, intervenable condition. - **Realistic Lifespan Targets:** Radical extension to hundreds of years requires interventions of extreme complexity with unclear near-term trade-offs. A more grounded framework: current long-tail outcomes, such as cognitively sharp 115-year-olds in isolated populations, becoming statistically common rather than exceptional across the general population. - **Cognitive Aging Drugs and Social Flexibility:** Drugs targeting cognitive aging could reduce the neurological crystallization of beliefs and preferences that hardens with age. This matters beyond music taste — it could increase an aging population's capacity to update worldviews, reducing generational ideological rigidity at a societal scale. - **Longevity as Socioeconomic Equalizer:** Healthier parents for longer reduces the caretaking burden that forces lower-income individuals to forgo career mobility. Halioua frames parental illness as a structural limiter on economic advancement, one that longevity medicine could partially dissolve by extending the window of parental independence. → NOTABLE MOMENT Halioua argues that parental health directly determines career opportunity — people whose parents fall ill cannot relocate or take risks, making longevity medicine a potential driver of socioeconomic mobility for those without financial safety nets. 💼 SPONSORS None detected 🏷️ Longevity Medicine, FDA Drug Approval, Cognitive Aging, Socioeconomic Mobility

Read Full Summary Listen

[Highlight] Why Dog Longevity Drugs Are the Fastest Path to Human Longevity with Celine Halioua

Venture Stories

Feb 19, 202612 min

AI Summary

→ WHAT IT COVERS Celine Halioua, founder of Loyal, explains why developing dog longevity drugs first is the fastest, most economically viable path to human longevity drugs, targeting five canine approvals by 2030. → KEY INSIGHTS - **Dogs as translational models:** Dog drug success rates are far more predictive for humans than mouse studies because dogs naturally develop dementia, cancer, and osteoarthritis like humans do. This could raise human drug trial success probability from 9% to roughly 40%, making billion-dollar human longevity studies financially viable. - **Dog drug economics as a funding engine:** Bringing a dog longevity drug from concept to approval costs approximately $50 million all-in, versus billions for human drugs. A small company can self-commercialize in the cash-pay pet market, generating revenue to fund subsequent human longevity research without big pharma dependency. - **Human longevity trial design tension:** Researchers face a catch-22 when designing human trials — intervening in older, high-risk individuals shortens study duration but reduces efficacy probability, while intervening earlier requires decades to see results. Choosing the right intervention window determines whether a company survives long enough to read out data. - **Patent protection blocks human longevity drugs:** Mechanisms well-established enough to clear safety bars for a human aging drug likely have insufficient remaining patent life to generate ROI post-approval. Identifying compounds with both strong biological evidence and viable patent protection is a core unsolved challenge for the field. → NOTABLE MOMENT Halioua argues the absence of human longevity drugs is not a biology problem — it is a financial and logistical one, a framing that redefines where researchers and investors should focus their efforts. 💼 SPONSORS None detected 🏷️ Dog Longevity, Biotech Drug Development, Human Aging Research, Venture Biotech Strategy

Read Full Summary Listen

Celine Halioua On The Science and Business of Making Dogs Live Longer

Venture Stories

Feb 11, 202653 min

AI Summary

→ WHAT IT COVERS Celine Halioua, founder of Loyal, explains her strategy to develop FDA-approved longevity drugs for dogs first, having raised over $250 million. She details milestone-based fundraising for biotech, regulatory pathways, clinical trials with 1,300 dogs, and plans to translate findings into human longevity treatments. → KEY INSIGHTS - **Milestone-Based Biotech Fundraising:** Deep tech companies raise capital differently than software startups. Instead of revenue metrics, biotech valuations increase as a fraction of future market value with each milestone that raises probability of FDA approval. Loyal mapped regulatory milestones (efficacy, safety, manufacturing) years in advance, understanding that investors underwrite specific FDA approvals, not just promising data. - **Conditional Approval Pathway:** Loyal secured FDA efficacy and safety approval for their first drug before full market launch, eliminating the primary biological risks that cause most drugs to fail. With manufacturing as the remaining hurdle, the company shifted from existential risk to execution risk. This transformed investor conversations from whether the drug works to when it launches, fundamentally changing valuation dynamics. - **Dogs as Human Drug Accelerators:** Developing longevity drugs in dogs first solves the human drug development paradox. Dogs age naturally with diseases like dementia and cancer, providing better translational biology than mice (9% human drug success rate). A dog lifespan study costs approximately $50 million versus billions for humans, with results in years not decades, creating viable economics for private funding. - **Clinical Trial Scale and Design:** Loyal runs the largest animal health clinical trial in history with 1,300 pet dogs across 70+ veterinary sites. The double-blind study tracks quality of life, disease development, and lifespan until death. This consumer-driven pharmaceutical model mirrors GLP-1 weight loss drugs, where pet owners request the treatment from veterinarians rather than traditional pharma marketing approaches. - **Revenue-Funded Moonshots Strategy:** Unlike most biotech companies that exit to pharma before commercialization, Loyal plans direct-to-consumer sales through veterinarians in a cash-pay system. This revenue engine (targeting five dog drug approvals by 2030) will fund expensive human longevity trials without relying on pharma acquisition, following the Tesla model of using current product revenue to fund increasingly ambitious next-generation development. → NOTABLE MOMENT Halioua reveals her early fundraising mistake: celebrating internal efficacy data a year before FDA approval, expecting investors to value it immediately. She learned investors cannot underwrite raw data without regulatory expertise, but can easily diligence a two-page FDA approval letter, teaching her to map milestones from the investor perspective, not the scientist perspective. 💼 SPONSORS None detected 🏷️ Biotech Fundraising, Longevity Medicine, FDA Approval Process, Animal Clinical Trials, Deep Tech Strategy

Read Full Summary Listen

Explore More

Science Episodes Best Science Podcasts (2026)

Never miss Celine Halioua's insights

Subscribe to get AI-powered summaries of Celine Halioua's podcast appearances delivered to your inbox weekly.

Start Free Today

No credit card required • Free tier available